New Immuno-Oncology Symposium to Be Held in 2017

New Immuno-Oncology Symposium to Be Held in 2017

Dr. Mary L. Disis
The field of immuno-oncology has revolutionized cancer care over the past decade and continues to yield new, exciting results. Recognizing immuno-oncology’s central place in modern oncology care, ASCO, in collaboration with the Society for Immunotherapy of Cancer (SITC), will be holding its first symposium on immuno-oncology, February 23 to 25, 2017, at the Hyatt Regency, in Orlando, Florida. Registration and abstract submissions will open in late August, with the abstract deadline on October 18.

Mary L. Disis, MD, FASCO, chair of the ASCO-SITC Clinical Immuno-Oncology Symposium Planning Committee, commented on the importance of holding the Symposium at this time.

“The field of immuno-oncology is rapidly advancing with new agents coming to the clinic each month. These drugs have new mechanisms of action compared to classic chemotherapy and unique side-effect profiles. Keeping oncologists up to date with the newest immuno-oncology science and clinical results is important for the use of these agents in the clinic.”

The Symposium will provide attendees a forum in which to discuss the range of new discoveries in immuno-oncology.

“There are so many new and exciting agents coming into the clinic for immunotherapy, from monoclonal antibodies targeting the next generation of checkpoint inhibitor proteins to oncolytic virus therapy, CAR T-cell therapy, and new approaches to cancer vaccines,” Dr. Disis said. “Having one meeting encapsulate the breadth of the field is truly exciting.”

The Symposium will shed light on the ways in which immune-based therapies have advanced beyond melanoma and will explore the clinical issues that arise from application within different disease sites.

Symposium attendees can expect “Immunology 101” sessions, as well as presentations on novel trial designs and high-throughput technologies used to better identify predictive biomarkers.

“There will be something for everyone, whether you are coming from outside of the field, a junior investigator coming into the field, or a clinician wanting to learn more about how to best treat your patients,” Dr. Disis said.  

–Shira Klapper